Study Title (official): Immunogen 0402: A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Objective of the study (Lay terms): To investigate the combination of mirvetuximab soravtansine (“IMGN853”) with standard therapies to learn the safety and tolerability, the dosage, and impact on tumor response.
Principal Investigator: Sanaz Memarzadeh, MD, PhD
Department: UCLA Department of OBGYN
For enrollment or criteria information, please contact:
For additional information regarding inclusion and exclusion criteria > ClinicalTrials.gov